- Home
- PBT vs AKBA Comparison
PBT vs AKBA Comparison
Compare PBT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- AKBA
- Stock Information
- Founded
- PBT 1980
- AKBA 2007
- Country
- PBT United States
- AKBA United States
- Employees
- PBT N/A
- AKBA N/A
- Industry
- PBT Oil & Gas Production
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- AKBA Health Care
- Exchange
- PBT Nasdaq
- AKBA Nasdaq
- Market Cap
- PBT 475.4M
- AKBA 559.0M
- IPO Year
- PBT N/A
- AKBA 2014
- Fundamental
- Price
- PBT $10.52
- AKBA $2.48
- Analyst Decision
- PBT
- AKBA Strong Buy
- Analyst Count
- PBT 0
- AKBA 4
- Target Price
- PBT N/A
- AKBA $6.63
- AVG Volume (30 Days)
- PBT 81.2K
- AKBA 3.8M
- Earning Date
- PBT 01-01-0001
- AKBA 05-08-2025
- Dividend Yield
- PBT 3.94%
- AKBA N/A
- EPS Growth
- PBT N/A
- AKBA N/A
- EPS
- PBT 0.55
- AKBA N/A
- Revenue
- PBT $27,114,144.00
- AKBA $184,909,000.00
- Revenue This Year
- PBT N/A
- AKBA $22.50
- Revenue Next Year
- PBT N/A
- AKBA $43.23
- P/E Ratio
- PBT $18.56
- AKBA N/A
- Revenue Growth
- PBT N/A
- AKBA N/A
- 52 Week Low
- PBT $8.01
- AKBA $0.80
- 52 Week High
- PBT $14.26
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- PBT 62.56
- AKBA 60.46
- Support Level
- PBT $9.73
- AKBA $2.25
- Resistance Level
- PBT $10.20
- AKBA $2.90
- Average True Range (ATR)
- PBT 0.34
- AKBA 0.15
- MACD
- PBT 0.07
- AKBA 0.01
- Stochastic Oscillator
- PBT 97.37
- AKBA 44.00
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.